Abstracts Archive - Page 518 of 2425 - ACR Meeting Abstracts

Abstract Number: 2270 • ACR Convergence 2022
Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Lida Kabir, Robert Maughan, Koralia Paschalaki, Anna Randi, David Carling, Deepa Arachchillage, Justin Mason and Charis Pericleous, Imperial College London, London, United Kingdom
Background/Purpose: The endothelium is a major target of pathogenic antiphospholipid antibodies (aPL) found in patients with antiphospholipid syndrome (APS). It is well established that aPL…
Abstract Number: PP10 • ACR Convergence 2022
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Brooklyn Johnson¹ and Kathleen Collins², ¹Memphis, TN, ²LeBonheur Children's Hospital, Memphis, TN
Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
Abstract Number: PP20 • ACR Convergence 2022
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
Melissa Allman, Michigan State University, Meridian Charter Township, MI
Background/Purpose: Trauma can have profound detrimental influences on our health and well-being. I am tangibly familiar with how trauma can impact the individual due to…
Abstract Number: 2221 • ACR Convergence 2022
The Molecular Endotypes of Type 1 and Type 2 SLE
Robert Robl¹, Amanda Eudy², Prathyusha Bachali³, Jennifer L Rogers⁴, Megan Clowse⁵, David Pisetsky⁶ and Peter lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Duke University, Raleigh, NC, ³AMPEL BioSolutions, Redmond, WA, ⁴Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University Medical Center, Durham, NC
Background/Purpose: To characterize the molecular landscape of patients with Type 1 and Type 2 systemic SLE erythematosus (SLE) by analyzing gene expression profiles from peripheral…
Abstract Number: 2269 • ACR Convergence 2022
Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Yu (Ray) Zuo¹, Sherwin Navaz¹, Alex Tsodikov¹, Katarina Kmetova², Claire Hoy¹, Srilakshmi Yalavarthi¹, Danieli Castro Oliveira de Andrade³, Maria G. Tektonidou⁴, Savino Sciascia⁵, Vittorio Pengo⁶, Guillermo Ruiz-Irastorza⁷, H Michael Belmont⁸, maria gerosa⁹, Paul fortin¹⁰, Guilherme de Jesús¹¹, D. Ware Branch¹², Laura Andreoli¹³, Esther Rodriguez Almaraz¹⁴, Michelle Petri¹⁵, Ricard Cervera¹⁶, Rohan Willis¹⁷, Doruk Erkan¹⁸ and Jason S Knight¹⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵University of Turin, Torino, Italy, ⁶Padova University Hospital, Padova, Italy, ⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ⁸NYU School of Medicine, New York, NY, ⁹University of Milan, Milano, Italy, ¹⁰CHU de Québec, Pavillon CHUL, Québec, Canada, ¹¹Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁶Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁷University of Texas Medical Branch, Galveston, TX, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils plays a role in the thromboinflammatory phenotype of APS. Previous work has demonstrated that…
Abstract Number: 1939 • ACR Convergence 2022
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
Merav Heshin-Bekenstein¹, amit ziv², NATASA TOPLAK³, Adi Miller Barmak⁴, Siman Lazauskas⁵, Danielle Kadishevich⁶, Efrat Ben Nun⁶, Esther Saiag⁷, Yonatan Butbul Aviel⁴, Gabi Shefer⁷, Sara Pel⁸, Ori Elkayam⁷ and Yosef Uziel⁹, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Meir Hospital, Kfar Saba, Israel, ³University of Ljubljana, Ljubljana, Slovenia, ⁴Rambam Medical Center, Haifa, Israel, ⁵Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Meir Medical Center, Kfar Saba, Israel, ⁷Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Background/Purpose: Long-term data on the safety and dynamics of the immune response to the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic…
Abstract Number: 2125 • ACR Convergence 2022
Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
Joseph Merola¹, Iain B McInnes², Arthur Kavanaugh³, Peter Nash⁴, Zhenyi Xue⁵, Vassilis Stakias⁶, Ann Eldred⁷, Sandra Ciecinski⁸, Kevin Douglas⁶ and Laura Coates⁹, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴School of Medicine, Griffith University, Sunshine Coast, Australia, ⁵AbbVie, Inc., Wilmington, DE, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie, Inc., Lake Bluff, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23.Methods: KEEPsAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: PP04 • ACR Convergence 2022
Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
Kara Wada, The Ohio State University, Columbus, OH
Background/Purpose: After years of ignoring my dry eyes and mouth, unrelenting fatigue, and body pain, an off-the-cuff comment from my dental hygienist finally pushed me…
Abstract Number: 2235 • ACR Convergence 2022
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial
Yifei Dai¹, Michael Rosenbluth², Michael Gendreau³, Nicolette Vega⁴, Zunera Ghalib⁴, Allison Kraus⁴ and Brian Keefe⁵, ¹Swing Therapeutics, Gainesville, FL, ²Swing Therapeutics, San Francisco, CA, ³GENDREAU CONSULTING, LLC, Poway, CA, ⁴Swing Therapeutics, San Francisco, ⁵Swing Therapeutics, New York, NY
Background/Purpose: Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT), a form of CBT, has…
Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Iain B McInnes¹, Philipp Sewerin², Mohamed Sharaf³, Michela Efficace⁴, May Shawi⁵, Michelle Perate⁶, Miriam Zimmermann⁷ and Laura Coates⁸, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁴Janssen Cilag SpA, Imperia, Italy, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
Abstract Number: 1953 • ACR Convergence 2022
Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively
Cristina Corrales¹, Fabricio Benavides Villanueva¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Virgi Portilla⁴, Ricardo Blanco⁵, Miguel Ángel González-Gay⁶ and Alfonso Corrales⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Patients with Rheumatoid Arthritis (RA) present an increased risk of mortality. In the last decades, mortality rates tended to decrease but cardiovascular (CV) events…
Abstract Number: 1940 • ACR Convergence 2022
Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers
Marci Macaraeg, Michael Matt, Grant Schulert, Elizabeth Baker and Elizabeth Handorf, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Unexplained, recurrent fevers are a common presentation to pediatric rheumatology and a cause of significant burden to affected families due to days of daycare…
Abstract Number: 1938 • ACR Convergence 2022
Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey
Francesca Minoia¹, Federica Lucioni¹, Merav Heshin-Bekenstein², Sebastiaan Vastert³, Christoph Kessel⁴, Yosef Uziel⁵, Lovro Lamot⁶, Nicola Ruperto⁷, Marco Gattorno⁸, Claudia Bracaglia⁹ and Natasa Toplak¹⁰, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ³Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, ⁵Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁶University Hospital Center Zagreb, Zagreb, Croatia, ⁷IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ⁸Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁰University Children's Hospital, University Medical Centre, Ljubljana, Slovenia
Background/Purpose: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) has become a healthcare issue worldwide. Since…
Abstract Number: 1941 • ACR Convergence 2022
Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
Melissa Argraves¹, Melissa Lerman¹, Julie Chase² and Samuel Goldfarb³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Kentucky, Lexington, KY, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].